{"protocolSection":{"identificationModule":{"nctId":"NCT04526210","orgStudyIdInfo":{"id":"ALXN1840-HV-103"},"organization":{"fullName":"Alexion Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants","officialTitle":"A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-10-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-05-28","type":"ACTUAL"},"completionDateStruct":{"date":"2021-05-28","type":"ACTUAL"},"studyFirstSubmitDate":"2020-08-19","studyFirstSubmitQcDate":"2020-08-24","studyFirstPostDateStruct":{"date":"2020-08-25","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-10-17","resultsFirstSubmitQcDate":"2022-10-17","resultsFirstPostDateStruct":{"date":"2023-08-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-10-17","lastUpdatePostDateStruct":{"date":"2023-08-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Alexion Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of bupropion.","detailedDescription":"The study is being conducted as a randomized, 2-period, 2-sequence, cross-over study to determine the effect of a single dose of ALXN1840 (perpetrator) on the single-dose bupropion (victim) kinetics in healthy male and female participants.\n\nThe study has a Screening Period (Day -28 to Day -2), two 11-day study periods (Day 1 to Day 11) with a minimum of 14 days between doses of bupropion, and an End of Study Visit (Day 15 ± 2 days) after Period 2 dosing. Participants will report to the clinical research unit on the day prior (Day -1) to both dosing periods. All participants will receive 1 treatment in each study period; treatment order will be defined based on randomization: Treatments A and B.\n\nThe time between dosing bupropion alone or in combination with ALXN1840 in each treatment sequence will be a minimum of 14 days.\n\nThe PK profile of ALXN1840 and bupropion will be determined by blood sampling following single dose administration."},"conditionsModule":{"conditions":["Wilson Disease"],"keywords":["Cytochrome P450","Healthy","ALXN1840"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":54,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment A","type":"EXPERIMENTAL","description":"Participants will receive bupropion.","interventionNames":["Drug: Bupropion Hydrochloride"]},{"label":"Treatment B","type":"EXPERIMENTAL","description":"Participants will receive bupropion with ALXN1840.","interventionNames":["Drug: ALXN1840","Drug: Bupropion Hydrochloride"]}],"interventions":[{"type":"DRUG","name":"ALXN1840","description":"ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.","armGroupLabels":["Treatment B"],"otherNames":["WTX101","Bis-choline tetrathiomolybdate","Tiomolibdate choline"]},{"type":"DRUG","name":"Bupropion Hydrochloride","description":"Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).","armGroupLabels":["Treatment A","Treatment B"],"otherNames":["Wellbutrin SR 150"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximum Observed Plasma Concentration (Cmax) of Bupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUCt) of Bupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUCinf) of Bupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"}],"secondaryOutcomes":[{"measure":"Cmax of Hydroxybupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"AUCt of Hydroxybupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"AUCinf of Hydroxybupropion With and Without the Coadministration of ALXN1840","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"Cmax of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"AUCt of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"AUCinf of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as any AE that began or worsened on or after the first dose of treatment until the end of study (EOS) or early termination (ET). An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","timeFrame":"Day 1 up to Day 15"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adequate venous access in the left or right arm to allow the collection of blood samples.\n* Body weight ≥ 45 to ≤ 100 kilograms (kg) and body mass index within the range of 18 to \\< 30 kg/meter squared.\n* Willing and able to follow protocol-specified contraception requirements.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* History or presence of/significant medical history.\n* Clinically significant multiple or severe allergies.\n* Lymphoma, leukemia, or any malignancy within 5 years.\n* Breast cancer within the past 10 years.\n* Serum creatinine \\> upper limit of normal (ULN) of the reference range.\n* Alanine aminotransferase, aspartate aminotransferase, or total bilirubin \\> ULN.\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n* QTc \\> 450 milliseconds (msec) for male participants or \\> 470 msec for female participants.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Clinical Trial Site","city":"Austin","state":"Texas","zip":"78744","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible participants were randomized to 1 of the two treatment sequences (A-B or B-A) on Day 1 prior to dosing in Period 1. Participants were scheduled to receive a single treatment (A or B) on Day 1 of each treatment period in the crossover design.","groups":[{"id":"FG000","title":"Treatment Sequence A-B","description":"Treatment A: Participants received a single oral dose of 1 × 150 milligrams (mg) bupropion hydrochloride (HCl) salt tablet in a fasted state on Day 1 of treatment period 1. Treatment B: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg enteric coated (EC) tablets of ALXN1840 in a fasted state on Day 1 of treatment period 2. There was a washout period of 14 days between the 2 treatment periods."},{"id":"FG001","title":"Treatment Sequence B-A","description":"Treatment B: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1. Treatment A: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 2. There was a washout period of 14 days between the 2 treatment periods."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Received at Least 1 Dose of Stud Drug","achievements":[{"groupId":"FG000","comment":"4 participants received Treatment A only.","numSubjects":"27"},{"groupId":"FG001","comment":"4 participants received Treatment B only.","numSubjects":"27"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Sponsor decision","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety set included all participants who received at least 1 dose of study intervention.","groups":[{"id":"BG000","title":"Treatment Sequence A-B","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1. Treatment B: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 2. There was a washout period of 14 days between the 2 treatment periods."},{"id":"BG001","title":"Treatment Sequence B-A","description":"Treatment B: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1. Treatment A: Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 2. There was a washout period of 14 days between the 2 treatment periods."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"54"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.6","spread":"8.68"},{"groupId":"BG001","value":"33.1","spread":"9.22"},{"groupId":"BG002","value":"32.3","spread":"8.90"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"38"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"34"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"14"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"37"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration (Cmax) of Bupropion With and Without the Coadministration of ALXN1840","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms (ng)/milliliter (mL)","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.64","spread":"31.6"},{"groupId":"OG001","value":"98.02","spread":"27.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric least square (LS) mean ratio","paramValue":"0.980","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.9415","ciUpperLimit":"1.0205"}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUCt) of Bupropion With and Without the Coadministration of ALXN1840","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1021","spread":"33.4"},{"groupId":"OG001","value":"1010","spread":"31.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric LS mean ratio","paramValue":"0.978","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.9344","ciUpperLimit":"1.0244"}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUCinf) of Bupropion With and Without the Coadministration of ALXN1840","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1049","spread":"32.9"},{"groupId":"OG001","value":"1039","spread":"31.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric LS mean ratio","paramValue":"0.981","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.9368","ciUpperLimit":"1.0269"}]},{"type":"SECONDARY","title":"Cmax of Hydroxybupropion With and Without the Coadministration of ALXN1840","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"286.5","spread":"53.8"},{"groupId":"OG001","value":"284.3","spread":"53.6"}]}]}]},{"type":"SECONDARY","title":"AUCt of Hydroxybupropion With and Without the Coadministration of ALXN1840","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11900","spread":"60.2"},{"groupId":"OG001","value":"11560","spread":"55.3"}]}]}]},{"type":"SECONDARY","title":"AUCinf of Hydroxybupropion With and Without the Coadministration of ALXN1840","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11960","spread":"59.5"},{"groupId":"OG001","value":"11630","spread":"54.8"}]}]}]},{"type":"SECONDARY","title":"Cmax of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"325.6","spread":"51.1"}]}]}]},{"type":"SECONDARY","title":"AUCt of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15010","spread":"68.1"}]}]}]},{"type":"SECONDARY","title":"AUCinf of Plasma Total Molybdenum With Coadministration of Bupropion","description":"Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only.","populationDescription":"PK analysis set included all participants who had sufficient plasma samples to have evaluable PK data for bupropion and/or total molybdenum (as a measure of ALXN1840) in plasma. Here, 'overall number of participants analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hours*ng/mL","timeFrame":"Pre-dose (Day 1) up to 336 hours post-dose","groups":[{"id":"OG000","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16130","spread":"65.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as any AE that began or worsened on or after the first dose of treatment until the end of study (EOS) or early termination (ET). An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","populationDescription":"Safety set included all participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to Day 15","groups":[{"id":"OG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2."},{"id":"OG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"50"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Day 1 up to Day 15","description":"Safety set included all participants who received at least 1 dose of study intervention.\n\nAll randomized participants except 8 received both assigned doses; 4 participants received only Treatment A and 4 participants received only Treatment B. In total, 50 participants received Treatment A and 50 participants received Treatment B. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given.","eventGroups":[{"id":"EG000","title":"Treatment A: Bupropion HCl","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet in a fasted state on Day 1 of treatment period 1 or 2.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":8,"otherNumAtRisk":50},{"id":"EG001","title":"Treatment B: Bupropion HCl + ALXN1840","description":"Participants received a single oral dose of 1 × 150 mg bupropion HCl salt tablet coadministered with 4 × 15 mg EC tablets of ALXN1840 in a fasted state on Day 1 of treatment period 1 or 2.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":11,"otherNumAtRisk":50}],"otherEvents":[{"term":"Chalazion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":50},{"groupId":"EG001","numAffected":2,"numAtRisk":50}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":4,"numAtRisk":50}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":2,"numAtRisk":50}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":2,"numAtRisk":50}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":1,"numAtRisk":50}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":1,"numAtRisk":50}]},{"term":"Oropharyngeal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":1,"numAtRisk":50}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":2,"numAtRisk":50}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":50},{"groupId":"EG001","numAffected":1,"numAtRisk":50}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":50},{"groupId":"EG001","numAffected":0,"numAtRisk":50}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Alexion Pharmaceuticals Inc.","organization":"Alexion Pharmaceuticals Inc.","email":"clinicaltrials@alexion.com","phone":"+1 855-752-2356"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-03-16","uploadDate":"2022-10-17T10:24","filename":"Prot_000.pdf","size":1674228},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-10-21","uploadDate":"2022-10-17T10:24","filename":"SAP_001.pdf","size":631438}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D006527","term":"Hepatolenticular Degeneration"}],"ancestors":[{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D001480","term":"Basal Ganglia Diseases"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D020739","term":"Brain Diseases, Metabolic, Inborn"},{"id":"D001928","term":"Brain Diseases, Metabolic"},{"id":"D009069","term":"Movement Disorders"},{"id":"D020271","term":"Heredodegenerative Disorders, Nervous System"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D008661","term":"Metabolism, Inborn Errors"},{"id":"D008664","term":"Metal Metabolism, Inborn Errors"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C020809","term":"tetrathiomolybdate"},{"id":"D016642","term":"Bupropion"}],"ancestors":[{"id":"D011427","term":"Propiophenones"},{"id":"D007659","term":"Ketones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}